Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
IPO Year: 2018
Exchange: NASDAQ
Website: ymabs.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | $3.00 | Neutral → Underperform | BofA Securities |
| 11/18/2024 | $23.00 | Outperform | Oppenheimer |
| 8/16/2024 | $20.00 | Overweight | Cantor Fitzgerald |
| 6/28/2024 | $21.00 | Buy | Truist |
| 5/10/2023 | $5.00 → $13.00 | Neutral → Outperform | Wedbush |
| 4/3/2023 | Buy → Neutral | Guggenheim | |
| 1/27/2023 | $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/5/2023 | Outperform → Market Perform | Cowen | |
| 12/2/2022 | $23.00 → $5.00 | Buy → Neutral | BofA Securities |
| 12/2/2022 | Buy → Neutral | BofA Securities |
Company's Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177Lu-DOTAIncreased tumor retention and total tumor uptake anticipated by using optimized universal RadiohaptenCompany plans to initiate a Trial 1001 Bridge study (Part 2A) with optimized Radiohapten, "Proteus", in 1H 2026 with data readout in 2H 2026; Part B of Trial 1001 anticipated to initiate with Proteus in 1H 2027 with data readout in 2H 2027Expanded Radiopharmaceutical pipeline to focus on target franchise areas in oncology, with specific prog
PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of GD2-SADA in recurrent or refractory metastatic solid tumors known to express GD2 in a trial in progress poster at the Advances in Neuroblastoma Research Meeting ("ANR") being held on May 25-28, 2025 in Washington, D.C. The trial in progress poster titled "A phase 1 trial of pretargeted radioimmunotherapy with GD2-SADA: 177Lu-DOTA in patients wit
PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will hold a virtual Radiopharmaceutical R&D update at 8:00 a.m. ET on Wednesday, May 28, 2025. During the virtual Radiopharmaceutical R&D update, Y-mAbs will discuss: Part A clinical data from the Company's ongoing Phase 1 GD2-SADA clinical trial (Trial 1001), including pharmacokinetic and dosimetry data; updates around the Company's nonclinical optimization studies
Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA®)Dosed first patient in Phase 1 clinical trial evaluating CD38-SADA pretargeted radioimmunotherapy in patients with Relapsed/Refractory non-Hodgkin Lymphoma (Trial 1201)The Company to host virtual Radiopharmaceutical R&D update discussing Part A clinical data from its Phase I GD2-SADA clinical trial (Trial 1001) and announcing radioimmunotherapy and pipeline strategy on May 28, 2025As of March 31, 2025, cash and cash equiv
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that naxitamab-gqgk (DANYELZA®) is recommended by the National Comprehensive Cancer Network® ("NCCN") Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a NCCN Category 2A treatment option for high-risk neuroblastoma. "We are very pleased with NCCN's update of the NCCN Guidelines to include naxitamab-gggk (DANYELZA). We believe this decision reinforces the
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the first quarter 2025 before the market open on Tuesday, May 13, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, May 13, 2025 at 8:00 a.m. ET. A live audio webcast of the call will be available on the Investor Relations section of the Company's website at https://ir.ymabs.com/events-and-presentat
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at the 2025 American Association of Cancer Research (AACR) Annual Meeting being held on April 25-30, 2025 in Chicago, IL. The poster titled "Preclinical and translational pharmacokinetic (PK) modeling of the self-assembling and disassembling (SADA) bispecific fusion protein
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that the first patient has been administered both the first protein dose and the 177Lu-DOTA imaging dose in its Phase 1 clinical trial evaluating the Company's Self-Assembly and Disassembly ("SADA") Pre-targeted Radioimmunotherapy ("PRIT") platform for the treatment of patients with relapsed or refractory non-Hodgkin Lymphoma (r/r NHL). This Phase 1 trial (Trial 1201) is a d
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed/refractory high-risk neuroblastoma in the journal Nature Communications. The article, titled "The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a
Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
10-Q - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
10-K/A - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
144 - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
424B5 - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
S-8 - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
10-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
8-K - Y-mAbs Therapeutics, Inc. (0001722964) (Filer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
3 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
3 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
SC 13G - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his resignation. Y-mAbs has commenced a search process for a successor. Mr. Kruse will remain in the Chief Financial Officer role until his successor is identified and joins the Company. He will then continue as a non-executive employee from the time his successor joins the Company through July 31, 2024, aft
NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Mary Tagliaferri, M.D. to the Company's Board of Directors, effective February 29, 2024. Dr. Tagliaferri brings nearly 30 years of biopharmaceutical industry experience and oncology therapeutic development expertise to the Y-mAbs Board of Directors. "We are thrilled to welcome Mary to our Board of Directors during such an exciting time for Y-mAbs," said
Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA®)Dosed first patient in Phase 1 clinical trial evaluating CD38-SADA pretargeted radioimmunotherapy in patients with Relapsed/Refractory non-Hodgkin Lymphoma (Trial 1201)The Company to host virtual Radiopharmaceutical R&D update discussing Part A clinical data from its Phase I GD2-SADA clinical trial (Trial 1001) and announcing radioimmunotherapy and pipeline strategy on May 28, 2025As of March 31, 2025, cash and cash equiv
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the first quarter 2025 before the market open on Tuesday, May 13, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, May 13, 2025 at 8:00 a.m. ET. A live audio webcast of the call will be available on the Investor Relations section of the Company's website at https://ir.ymabs.com/events-and-presentat
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of DANYELZACash and cash equivalents of $67.2 million held as of December 31, 2024, reflects $11.4 million Total Annual Cash Investment in the full year 2024Management announces Full Year 2025 guidance around Total Revenue, Operating Expenses, and Cash Investment and First Quarter 2025 guidance around Total Revenue The Company will host a conference call on Tuesday, March 4, 2025, at 8:00 a.m. ET NEW YOR
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025. Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of
Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024Achieved extension of primary DANYELZA U.S. patent through February 2034Continued geographic expansion of DANYELZA with new market revenues recorded in the third quarter from TurkeyManagement reiterates Full Year 2024 guidance around Total Net Revenue, Operating Expenses, and Cash Flow Investment The Company will host a conference call on Friday, November 8, 2024, at 8:00 a.m. ET NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):Investors (international):(877) 407-0792(201) 689-8263 To access a live webcast of the update,
Reported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increaseContinued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong KongPart A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter of 2024Appointed Peter Pfreundschuh as the new Chief Financial Officer and radiopharma industry veteran Norman LaFrance, M.D. as Chief Development Officer Cash and cash equivalents of $77.8 million held as of June 30, 2024, reflects $0.8 million cash burn in the six months ended June 30, 2024;
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report second quarter 2024 financial and operating results before market open on Monday, August 12, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET. Conference call and webcast details: Investors (domestic):(877) 407-0792Investors (international):(201) 689-8263 To access a live webcast of the update, please use this
Reported U.S. DANYELZA® net product revenues of $18.6 million for the first quarter of 2024, representing a YoY increase of 11% Reported Worldwide DANYELZA net product revenues of $19.4 million for the first quarter of 2024, representing a 4% YoY decrease due to international volumesCash and cash equivalents of $75.7 million as of March 31, 2024, and cash burn of only $2.9 million for the quarter ended March 31, 2024 Management reiterates full year 2024 financial guidance and anticipated cash runway into 2027The Company will host a conference call on Wednesday, May 8, 2024, at 8:00 a.m. ET NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NA
NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter ended March 31, 2024, on Tuesday, May 7, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Wednesday, May 8, 2024, at 8:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Sue Smith, Chief Commercial Officer; Vignesh Rajah, Chief Medical Officer; Bo Kruse, Chief Financial Officer; and Thomas Gad, Founder, Vice Chair and Chief Business Officer. C
BofA Securities downgraded Y-mAbs Therapeutics from Neutral to Underperform and set a new price target of $3.00
Oppenheimer initiated coverage of Y-mAbs Therapeutics with a rating of Outperform and set a new price target of $23.00
Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with a rating of Overweight and set a new price target of $20.00
Truist initiated coverage of Y-mAbs Therapeutics with a rating of Buy and set a new price target of $21.00
Wedbush upgraded Y-mAbs Therapeutics from Neutral to Outperform and set a new price target of $13.00 from $5.00 previously
Guggenheim downgraded Y-mAbs Therapeutics from Buy to Neutral
Morgan Stanley downgraded Y-mAbs Therapeutics from Equal-Weight to Underweight and set a new price target of $4.00
Cowen downgraded Y-mAbs Therapeutics from Outperform to Market Perform
BofA Securities downgraded Y-mAbs Therapeutics from Buy to Neutral and set a new price target of $5.00 from $23.00 previously
BofA Securities downgraded Y-mAbs Therapeutics from Buy to Neutral
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)
4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)